Spots Global Cancer Trial Database for New Markers for Treatment Response to Radiotherapy in Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: New Markers for Treatment Response to Radiotherapy in Prostate Cancer
Official Title: New Markers for Treatment Response to Radiotherapy in Prostate Cancer
Study ID: NCT06159998
Conditions
Interventions
Study Description
Brief Summary: The actual follow-up of patients undergoing definite radiotherapy for prostate cancer includes regular measurements of prostate specific antigen (PSA). Successful radiotherapy is critically dependent on local control of cancer; however, PSA takes 2-3 years to reach a nadir after therapy. We aim at collecting blood/urine after prostate massage before, and after radiotherapy in order to define new markers predicting local control earlier and more precisely than PSA.
Detailed Description: Patients will be closely followed for 5 years (weeks 0, 2, 4, 6, and months 2, 3, 6, 9, 12, 18, 24, and then yearly). Each assessment includes PSA measurement, urine collection after prostatic massage, and blood collection.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Department of Urology, University Hospital Basel, Basel, Basel-Stadt, Switzerland
Contact Details
Name: Cyrill A Rentsch, MD-PhD
Affiliation: University Hospital, Basel, Switzerland
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
